CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis - PubMed

Affiliations

• PMID: 17083975
• DOI: 10.1016/j.molimm.2006.09.032

Comparative Study

CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis

Michael Mølhøj et al. Mol Immunol. 2007 Mar.

Abstract

Many kinds of bispecific antibodies recruiting T cells for cancer therapy have been developed. Side-by-side comparison has shown that CD19-/CD3-bispecific antibodies of the diabody, tandem diabody (Tandab) and quadroma format had similar cytotoxic activity, with Tandab being the most active format. Tandab has also been claimed to be superior to single-chain (sc) Fv-based bispecific constructs although data from a side-by-side comparison are not available. In this study, we compared side-by-side MT103 (bscCD19xCD3), a single-chain bispecific antibody of the BiTE class, with a CD19-/CD3-bispecific representative of the Tandab class. Based on literature data, we have constructed, produced and characterized the LL linker version of Tandab, which was reported to be the most active version of Tandab proteins. A dimeric protein of 114kDa was obtained that showed proper bispecific binding to CD3- and CD19-positive cells and could redirect both pre-stimulated and unstimulated human T cells for lysis of human B lymphoma lines Raji, MEC-1 and Nalm-6. Raji cells were lysed at a half-maximal concentration (EC50) of 10 nM Tandab using pre-stimulated T cells, which closely matched the published activity of LL-Tandab with this particular cell line. MT103 had between 700- and 8000-fold higher efficacy than Tandab for redirected lysis of the three human B lymphoma lines. These data demonstrate that under identical experimental conditions, the BiTE format has far superior activity compared to the Tandab format and is also superior to conventional diabody and quadroma formats. The extraordinary potency of the BiTE class and its representative MT103 may translate into improved anti-tumor activity, lower dosing and lower costs of production compared to other bispecific antibody formats.

Comment in

• Flawed TandAb production.

  Little M, Kipriyanov S. Little M, et al. Mol Immunol. 2007 Apr;44(11):3083; author reply 3084. doi: 10.1016/j.molimm.2007.01.006. Epub 2007 Mar 6. Mol Immunol. 2007. PMID: 17339053 No abstract available.

Similar articles

• Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation.

  Cochlovius B, Kipriyanov SM, Stassar MJ, Schuhmacher J, Benner A, Moldenhauer G, Little M. Cochlovius B, et al. Cancer Res. 2000 Aug 15;60(16):4336-41. Cancer Res. 2000. PMID: 10969772

• A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.

  Reusch U, Duell J, Ellwanger K, Herbrecht C, Knackmuss SH, Fucek I, Eser M, McAleese F, Molkenthin V, Gall FL, Topp M, Little M, Zhukovsky EA. Reusch U, et al. MAbs. 2015;7(3):584-604. doi: 10.1080/19420862.2015.1029216. MAbs. 2015. PMID: 25875246 Free PMC article.

• Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.

  Kipriyanov SM, Moldenhauer G, Schuhmacher J, Cochlovius B, Von der Lieth CW, Matys ER, Little M. Kipriyanov SM, et al. J Mol Biol. 1999 Oct 15;293(1):41-56. doi: 10.1006/jmbi.1999.3156. J Mol Biol. 1999. PMID: 10512714

• RECRUIT-TandAbs: harnessing the immune system to kill cancer cells.

  McAleese F, Eser M. McAleese F, et al. Future Oncol. 2012 Jun;8(6):687-95. doi: 10.2217/fon.12.54. Future Oncol. 2012. PMID: 22764766 Review.

• Recombinant bispecific antibodies for cancer therapy.

  Kontermann RE. Kontermann RE. Acta Pharmacol Sin. 2005 Jan;26(1):1-9. doi: 10.1111/j.1745-7254.2005.00008.x. Acta Pharmacol Sin. 2005. PMID: 15659107 Review.

Cited by

• Comparison of Anticancer Drug Toxicities: Paradigm Shift in Adverse Effect Profile.

  Basak D, Arrighi S, Darwiche Y, Deb S. Basak D, et al. Life (Basel). 2021 Dec 29;12(1):48. doi: 10.3390/life12010048. Life (Basel). 2021. PMID: 35054441 Free PMC article. Review.

• ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy.

  Harwood SL, Alvarez-Cienfuegos A, Nuñez-Prado N, Compte M, Hernández-Pérez S, Merino N, Bonet J, Navarro R, Van Bergen En Henegouwen PMP, Lykkemark S, Mikkelsen K, Mølgaard K, Jabs F, Sanz L, Blanco FJ, Roda-Navarro P, Alvarez-Vallina L. Harwood SL, et al. Oncoimmunology. 2017 Sep 27;7(1):e1377874. doi: 10.1080/2162402X.2017.1377874. eCollection 2017. Oncoimmunology. 2017. PMID: 29296540 Free PMC article.

• Development and characterization of a novel luciferase based cytotoxicity assay.

  Matta H, Gopalakrishnan R, Choi S, Prakash R, Natarajan V, Prins R, Gong S, Chitnis SD, Kahn M, Han X, Chaudhary V, Soni A, Sernas J, Khan P, Wang D, Chaudhary PM. Matta H, et al. Sci Rep. 2018 Jan 9;8(1):199. doi: 10.1038/s41598-017-18606-1. Sci Rep. 2018. PMID: 29317736 Free PMC article.

• Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs.

  AlDeghaither D, Smaglo BG, Weiner LM. AlDeghaither D, et al. J Clin Pharmacol. 2015 Mar;55 Suppl 3(0 3):S4-20. doi: 10.1002/jcph.407. J Clin Pharmacol. 2015. PMID: 25707963 Free PMC article. Review.

• Let's Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia.

  Deak D, Pop C, Zimta AA, Jurj A, Ghiaur A, Pasca S, Teodorescu P, Dascalescu A, Antohe I, Ionescu B, Constantinescu C, Onaciu A, Munteanu R, Berindan-Neagoe I, Petrushev B, Turcas C, Iluta S, Selicean C, Zdrenghea M, Tanase A, Danaila C, Colita A, Colita A, Dima D, Coriu D, Einsele H, Tomuleasa C. Deak D, et al. Front Immunol. 2019 Dec 20;10:2856. doi: 10.3389/fimmu.2019.02856. eCollection 2019. Front Immunol. 2019. PMID: 31921126 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information